IQVIA Holdings Inc. $IQV Shares Bought by TD Private Client Wealth LLC

TD Private Client Wealth LLC grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 2,060.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,938 shares of the medical research company’s stock after buying an additional 2,802 shares during the quarter. TD Private Client Wealth LLC’s holdings in IQVIA were worth $558,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in IQV. Asset Dedication LLC grew its holdings in shares of IQVIA by 224.0% in the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 168 shares during the period. Trust Co. of Toledo NA OH acquired a new position in IQVIA in the 2nd quarter valued at about $39,000. J.Safra Asset Management Corp grew its stake in shares of IQVIA by 208.6% in the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after buying an additional 169 shares during the period. Rothschild Investment LLC increased its holdings in shares of IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after buying an additional 124 shares during the last quarter. Finally, NewSquare Capital LLC raised its position in shares of IQVIA by 185.3% during the 2nd quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after buying an additional 189 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Baird R W upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 29th. UBS Group raised their price target on shares of IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. Cowen lowered IQVIA from a “buy” rating to a “hold” rating in a report on Monday, November 3rd. Finally, Robert W. Baird set a $258.00 price target on IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $249.19.

IQVIA Stock Down 1.3%

IQV stock opened at $238.03 on Friday. The stock has a market cap of $40.54 billion, a P/E ratio of 32.65, a PEG ratio of 2.45 and a beta of 1.36. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The company’s 50 day moving average is $227.30 and its two-hundred day moving average is $203.05.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.